Novo Nordisk's Oral Weight-Loss Pill Faces Its Moment of Truth Amid Trial Setback and Lilly Legal Fight
Published on 08/03/2026 at 15:02 | Redaktion boerse-global.de
The options market is signaling that Novo Nordisk's upcoming half-year report could deliver one of the most volatile trading days the stock has seen this year. When the Danish pharma giant releases its numbers on Wednesday, August 5, investors will be looking past the headline figures to a single, defining question: can the Wegovy pill sustain the explosive momentum it built in the first quarter?
That oral semaglutide product generated 2.26 billion Danish kroner in revenue during Q1 — nearly double what analysts had projected. The bar for Q2 is now set accordingly high, with consensus estimates pointing to roughly $10.58 billion in group-wide sales and adjusted earnings per share of $0.76.
A Pill That's Pulling in New Patients
Morningstar analysts have described the Wegovy tablet as a "bright spot" in Novo's portfolio, and the early US numbers back that up. Within its first five months on the American market, the pill surpassed 3 million prescriptions. CEO Mike Doustdar recently pegged Wegovy's share of new US obesity prescriptions at 65 percent.
Perhaps more telling: over 80 percent of new pill prescriptions are going to patients who have never previously used a GLP-1 therapy. The tablet is expanding the addressable patient pool rather than merely cannibalizing Novo's own injectable franchise — a distinction that matters for the growth narrative.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
ZEUS Failure Complicates the Picture
The earnings release arrives with a fresh overhang. On Friday, July 31, Novo confirmed that its Phase 3 ZEUS trial missed its primary endpoint. The drug candidate ziltivekimab, developed to reduce major cardiovascular events in patients with chronic kidney disease and inflammation, delivered a hazard ratio of 0.99 — effectively no benefit over placebo.
The failure triggers a non-cash impairment charge in the third quarter, though management insists its 2026 guidance for adjusted operating profit remains untouched. Still, the setback raises the stakes for the GLP-1 franchise to deliver convincing growth.
Legal Escalation With Eli Lilly
Novo is also taking the fight to its biggest rival in the courtroom. In July 2026, the company filed a lawsuit in the US accusing Eli Lilly of misleading advertising for its competing products Zepbound and Mounjaro. The complaint alleges Lilly relies on outdated study data to imply product superiority while omitting important context about the efficacy of Novo's own high-dose formulations.
The legal clash underscores just how fierce competition has become in a market analysts project could reach $150 billion globally by 2030. Lilly's oral competitor Foundayo launched in April 2026, though early prescription data shows it trailing the Wegovy pill. Novo is also preparing a pricing move: starting January 2027, list prices for Wegovy and Ozempic will drop significantly to improve patient access over the long term.
A Stock Under Pressure
The market has already been voting with its feet. The shares closed Friday at €41.10, roughly 25 percent below the 52-week high of €54.86 set in January. The stock shed more than 6 percent last week alone, with Friday's session seeing an 8.48 percent decline that left the price hovering around €40.90 — essentially flat against its 50-day moving average, a sign of the market's current uncertainty.
Options traders are bracing for a move of roughly 8 percent around the earnings date, according to Saxo Bank calculations. That implies a potential trading range of approximately $44.90 to $52.60 for the US listing, though the estimate includes several days of drift beyond the actual report. Historical reactions have been more muted: following the last two quarterly releases, the stock fell 6.7 percent and 5.4 percent respectively on the next trading day, per Bloomberg data cited by Saxo.
Lower Expectations, Divided Analyst Views
The bar has been lowered considerably. Consensus estimates for quarterly earnings per share have been cut by about 24 percent over the past year to roughly 5.02 Danish kroner — a development that could make a positive surprise easier to achieve.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Analyst sentiment is notably split. Among 26 analysts covering the Copenhagen-listed B-shares, the average rating stands at "Hold" with a mean price target of 317.20 Danish kroner. Individual targets range wildly from 200 to 453 kroner, reflecting deep disagreement over how the obesity race against Lilly will play out. The US side looks somewhat more constructive: a broader panel of 37 analysts shows a 68 percent buy rating with an average 12-month target of $51.19.
What Actually Moves the Stock
Lilly's positive Phase 3 data for retatrutide, released July 23, adds another layer of competitive pressure. Novo still commands roughly 89 percent of the US oral GLP-1 market by volume since the Wegovy pill's January launch, but Lilly's injectable pipeline looms large.
Since the Q1 report, Novo's US listing has gained about 8.7 percent. A guidance raise for the full year is widely anticipated and may already be priced in. With earnings expectations trimmed and the forecast bump largely anticipated, the market's reaction could hinge less on the raw numbers and more on management's commentary around US pricing dynamics and the pace of the Wegovy pill's international rollout.
The elevated implied volatility tells the story: investors are treating this as a binary event. Wednesday will reveal whether the oral Wegovy growth story can absorb the mounting competitive and pricing pressure — and whether the ZEUS disappointment was a one-off setback or a sign of deeper cracks in the pipeline.
Ad
Novo Nordisk Stock: New Analysis - 3 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
